Lenalidomide mediated immune regulation in cancer immunotherapy
碩士 === 中華科技大學 === 健康科技研究所在職專班 === 99 === Recent preclinical and clinical findings suggest that the immunomodulatory drug (IMiDs) Lenalidomide has dual mechanism of action, involving both the direct tumoricidal activity and immunomodulation, which can result in rapid and sustained control of Multip...
Main Authors: | Cher Chang, 張竹君 |
---|---|
Other Authors: | Ming-Shen Dai |
Format: | Others |
Language: | zh-TW |
Published: |
2011
|
Online Access: | http://ndltd.ncl.edu.tw/handle/22555319154780341874 |
Similar Items
-
Lenalidomide targets the T-cell co-stimulatory pathway to mediate immune modulation
by: Mcdaniel, Jessica Marie
Published: (2012) -
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy
by: Annika Nelde, et al.
Published: (2018-04-01) -
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
by: Gustav J Ullenhag, et al.
Published: (2017-01-01) -
Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy
by: Robin Jacob, MD, et al.
Published: (2020-11-01) -
Regulation of cGAS‐Mediated Immune Responses and Immunotherapy
by: Abdullah F. U. H. Saeed, et al.
Published: (2020-03-01)